UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 123

Sortiert nach

How I treat hyperleukocytosis in acute myeloid leukemia

Blood, 2015-05, Vol.125 (21), p.3246-3252

2015

Volltextzugriff (PDF)

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

Blood, 2013-07, Vol.122 (1), p.83-92

2013

Volltextzugriff (PDF)

Gemtuzumab ozogamicin in AML: the next chapter

Blood, 2023-11, Vol.142 (20), p.1673

Röllig, Christoph

2023

Volltextzugriff (PDF)

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Blood, 2011-11, Vol.118 (21), p.1445-1445

2011

Volltextzugriff (PDF)

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Blood, 2012-11, Vol.120 (21), p.2017-2017

2012

Volltextzugriff (PDF)

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Blood, 2012-11, Vol.120 (21), p.4167-4167

2012

Volltextzugriff (PDF)

Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL

Blood, 2010-11, Vol.116 (21), p.754-754

2010

Volltextzugriff (PDF)

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Blood, 2011-11, Vol.118 (21), p.935-935

2011

Volltextzugriff (PDF)

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

Blood, 2010-11, Vol.116 (21), p.2154-2154

2010

Volltextzugriff (PDF)

The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience

Blood, 2010-11, Vol.116 (21), p.1326-1326

2010

Volltextzugriff (PDF)

PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia

Blood, 2010-11, Vol.116 (21), p.2156-2156

2010

Volltextzugriff (PDF)

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53-Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Blood, 2012-11, Vol.120 (21), p.921-921

2012

Volltextzugriff (PDF)

Appearance of Mature 6-Sulfo LacNAc+ Dendritic Cells In Early and Late Engraftment After Allogeneic Stem Cell Transplantation

Blood, 2010-11, Vol.116 (21), p.3720-3720

2010

Volltextzugriff (PDF)

A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial

Blood, 2010-11, Vol.116 (21), p.4000-4000

2010

Volltextzugriff (PDF)

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Blood, 2010-11, Vol.116 (21), p.2180-2180

2010

Volltextzugriff (PDF)

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Blood, 2010-11, Vol.116 (21), p.679-679

2010

Volltextzugriff (PDF)

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Blood, 2010-11, Vol.116 (21), p.1945-1945

2010

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(123)

Sprache

Englisch
(123)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Hematology
(14)
Humans
(14)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Aged
(10)
Female
(9)
Leukemia, Myeloid, Acute - Genetics
(9)
Male
(9)
Middle Aged
(8)
Adult
(7)
Prognosis
(7)
Follow-Up Studies
(5)
Mutation
(5)
Aged, 80 And Over
(4)
Disease-Free Survival
(4)
Leukemia, Myeloid, Acute - Drug Therapy
(4)
Leukemia, Myeloid, Acute - Mortality
(4)
Leukemia, Myeloid, Acute - Therapy
(4)
Nuclear Proteins - Genetics
(4)
Retrospective Studies
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
(123)
Single Journals
(123)
MEDLINE
(14)

Menü

Weitere Dienste

Einstellungen

How I treat hyperleukocytosis in acute myeloid leukemia

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

Gemtuzumab ozogamicin in AML: the next chapter

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience

PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53-Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Appearance of Mature 6-Sulfo LacNAc+ Dendritic Cells In Early and Late Engraftment After Allogeneic Stem Cell Transplantation

A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

Aktive Filter

Suchergebnisse filtern